Abstracts tagged "Biomarkers"

Abstract Number: 0023 • ACR Convergence 2022
New Biomarkers in Hand Osteoarthritis: The Micro-RNA Signature
Maxime Auroux¹, Marjorie Millet², Blandine Merle², Elisabeth Fontanges¹, Florence Duvert¹, Evelyne Gineyts³, Jean-Charles Rousseau³, Olivier Borel², Alexandre Mercier¹, Eric LESPESSAILLES⁴ and Roland Chapurlat¹, ¹Hospices Civils de Lyon, LYON, France, ²INSERM U1033, LYON, France, ³INSERM 1033, Lyon, France, ⁴Regional hospital centre of Orleans, France, ORLEANS, Centre, France
Background/Purpose: Hand osteoarthritis (HOA) is a highly prevalent disease, associated with important disability and socio-economic burden. Erosive HOA, almost exclusively found in women, induces more…
Abstract Number: 0300 • ACR Convergence 2022
Exposure-Response Analyses of Upadacitinib Effects on Plasma Biomarkers in Rheumatoid Arthritis Patients
Yuli Qian¹, Fang Cai², Thierry Sornasse³, Jie Shen¹, Heidi Camp⁴ and Mohamed-Eslam Mohamed¹, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie, Redwood City, CA, ³AbbVie, South San Francisco, CA, ⁴Abbvie, Winnetka, IL
Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the treatment of moderately-to-severely active rheumatoid arthritis (RA). Previous investigations demonstrated UPA modulates…
Abstract Number: 0536 • ACR Convergence 2022
Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Andrea Fava¹, Laurence S Magder², Daniel W. Goldman³, Jill Buyon⁴, Betty Diamond⁵, Joel Guthridge⁶, William Apruzzese⁷, Derek Fine¹, Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Peter Izmirly⁴, H Michael Belmont⁸, Anne Davidson⁵, Maria Dall'Era⁹, Deepak Rao⁷, Arnon Arazi¹⁰, Nir Hacohen¹¹, Soumya Raychaudhuri⁷, the Accelerating Medicines Partnership (AMP) RA/SLE¹² and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Brigham and Women's Hospital, Boston, MA, ⁸NYU School of Medicine, New York, NY, ⁹University of California, San Francisco, San Francisco, ¹⁰Feinstein Institutes for Medical Research, Melrose, MA, ¹¹Broad Institute, Cambridge, MA, ¹²Multiple Insitutions
Background/Purpose: A decline of urine protein-to-creatinine ratio (UPCR) to < 0.5 is associated with better long-term preservation of kidney function in lupus nephritis (LN). UPCR…
Abstract Number: 0656 • ACR Convergence 2022
Association Study Identified HLA-DQA1 as a Genetic Risk of Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension
Junyan Qian¹, Ying Chen², Xinzhuang Yang³, Qian Wang⁴, JIULIANG ZHAO⁵, Xiaoyue Deng¹, Shengjie Li³, Yongtai Liu⁶, Zhuang Tian⁶, Juan Shen², Qijun Liao², Yanhong Wang⁷, Xianbo Zuo⁸, Xuejun Zhang⁹, MENGTAO LI¹, Yong Cui⁸, Xueqing Yu¹⁰ and Xiaofeng Zeng¹¹, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, ²BGI-Shenzhen, Shenzhen, China, ³Medical Research Center, State Key laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁴Peking Union Medical College Hospital, Beijing, China, ⁵Beijing Union Medical College Hospital, Beijing, China, ⁶Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, ⁷Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, China Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁸Department of Dermatology, China-Japan Friendship Hospital, Beijing, China, ⁹Institute of Dermatology, Anhui Medical University, Hefei, China, ¹⁰Division of Nephrology, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China, ¹¹Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: Pulmonary arterial hypertension (PAH) is a rare and severe complication of systemic lupus erythematosus (SLE). Human leucocyte antigen (HLA) gene variants in the major…
Abstract Number: 0933 • ACR Convergence 2022
Exploratory Study of the Usefulness of TNFAIP3 Genetic Variants in Predicting Response to Methotrexate in Early Arthritis Patients
Ana Triguero¹, JUAN BALDIVIESO ACHA², Emilia Roy Vallejo³, Patricia Quiroga-Colina⁴, Irene Maria Llorente Cubas², Rosario Garcia-Vicuña⁵, amaya Puig kröger⁶ and Isidoro Gonzalez², ¹Hospital Universitario La Princesa, Madrid, Spain, ²Hospital Universitario de La Princesa, Madrid, Spain, ³Internal Medicine Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁶Laboratory of Immunometabolism, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: We recently described that methotrexate (MTX) could exert its immunomodulatory effect through the induction of A20 expression , a protein that negatively regulates NFkB…
Abstract Number: 1221 • ACR Convergence 2022
Multi-Center Validation of Cell-Bound Complement Activation Products and a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia
Mark Rudolph¹, Scott Rey¹, Alan Kivitz², Stuart Silverman³, Roland Staud⁴ and Roberta Alexander¹, ¹Exagen, Inc., Vista, CA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of Florida, Gainesville, FL
Background/Purpose: A 2016 article in Lupus Science & Medicine (Wallace et al. 2016) described the ability of cell-bound complement activation products (CB-CAPs) on their own--…
Abstract Number: 1487 • ACR Convergence 2022
Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
James Krueger¹, Kilian Eyerich², Dennis McGonagle³, Carrie Greving⁴, Kacey Sachen⁴, Deepa Hammaker⁴, Phuc Bao⁴, Eilyn Lacy⁴, M. Merle Elloso⁵, Yevgeniya Orlovsky⁵, Iain B McInnes⁶ and Anne Fourie⁷, ¹The Rockefeller University, New York, NY, ²Technical University, Munich, Germany / Karolinska Institute, Stockholm, Sweden, ³University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁴Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁷Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA
Background/Purpose: Clinically relevant differences between therapeutic antibodies against the same target may relate to their unique molecular attributes. Differences in therapeutic profiles across the domains…
Abstract Number: 1655 • ACR Convergence 2022
Belimumab Disrupts Memory B-Cell Trafficking in Patients with Systemic Lupus Erythematosus
Eline J. Arends¹, Mihaela Zlei², Christopher M. Tipton³, Jasna Cotic⁴, Zgjim Osmani¹, Fenna J. De Bie², Sylvia W.A. Kamerling¹, Andre Van Maurik⁵, Richard Dimelow⁶, Yun Irene Gregan⁷, Norma Lynn Fox⁸, Ton J. Rabelink¹, David A. Roth⁹, Iñaki Sanz¹⁰, Jacques J.M. Van Dongen², Cees Van Kooten¹ and Onno Teng¹¹, ¹Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Immunology, Leiden University Medical Center, Leiden, Netherlands, ³Lowance Center for Human Immunology, Emory University School of Medicine, Atlanta, GA, ⁴Clinical Statistics, GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, United Kingdom, ⁶GlaxoSmithKline, Clinical Biomarker Group, Stevenage, United Kingdom, ⁷GlaxoSmithKline, Clinical Science Immunology, Collegeville, PA, ⁸GlaxoSmithKline, Clinical Development *At time of study, Collegeville, PA, ⁹GlaxoSmithKline, Research and Development, Collegeville, PA, ¹⁰Emory University, Atlanta, GA, ¹¹Leiden University Medical Center, Leiderdorp, Netherlands
Background/Purpose: Belimumab (BEL), a recombinant human monoclonal antibody directed against B-cell activating factor (BAFF), is the first approved biological agent for patients (pts) with active…
Abstract Number: 1898 • ACR Convergence 2022
Radiographic Osteoarthritis Progression Can Be Predicted via Pyrosequencing Analysis of Baseline Peripheral Blood
Chris Dunn¹, Cassandra Velasco², Leoni Schlupp³, Emmaline Prinz³, Vladislav Izda⁴, Liubov Arbeeva⁵, Yvonne Golightly⁶, Amanda Nelson⁶ and Matlock Jeffries³, ¹University of Oklahoma Health Sciences Center, Edmond, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, New York, NY, ⁵University of North Carolina Chapel Hill, Chapel Hill, NC, ⁶UNC School of Medicine, Chapel Hill, NC
Background/Purpose: Knee osteoarthritis (OA) is a heterogeneous disease characterized by a variety of clinical and molecular phenotypes. However, we do not yet have robust biomarkers…
Abstract Number: 2099 • ACR Convergence 2022
Drug Repurposing for Treating Lupus Nephritis Based on Transcriptome Profiling and Autoimmunity-Related Serological Markers
Ioannis Parodis¹, Julius Lindblom¹, Daniel Toro-Domínguez², Elena Carnero-Montoro², Maria Orietta Borghi³, Jessica Castillo⁴, Yvonne Enman⁵, Chandra Mohan⁴, Marta Alarcon-Riquelme² and Guillermo Barturen², ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, ⁴University of Houston, Houston, TX, ⁵Karolinska Institutet, Sundbyberg, Sweden
Background/Purpose: LN is one of the most severe organ manifestations of SLE and constitutes an important cause of morbidity and death among patients with SLE…
Abstract Number: 2252 • ACR Convergence 2022
Higher Matrix Metalloproteinase Levels Are Predictive of Incident Interstitial Lung Disease Among a Cohort of US Veterans with Rheumatoid Arthritis
Brent Luedders¹, Dana Ascherman², Joshua Baker³, Michael Duryee¹, Yangyuna Yang¹, Punyasha Roul⁴, Katherine Wysham⁵, Paul Monach⁶, Andreas Reimold⁷, Gail Kerr⁸, Gary Kunkel⁹, Grant Cannon¹⁰, Jill Poole¹, Geoffrey Thiele¹, Ted Mikuls¹¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴UNMC, Omaha, NE, ⁵VA Puget Sound/University of Washington, Seattle, WA, ⁶VA Boston Healthcare System, Boston, MA, ⁷University of Texas Southwestern Medical Center, Dallas, TX, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹University of Utah, Salt Lake City, UT, ¹⁰Retired, Salt Lake City, UT, ¹¹Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Matrix metalloproteinases (MMPs) degrade extracellular matrix and have been implicated to play a role in a number of fibrotic processes. Specifically, MMPs have been…
Abstract Number: 0027 • ACR Convergence 2022
Associations of Serum C3f with Selected Biomarkers and Radiographic and Clinical Features of Knee Osteoarthritis
Yulia Liem¹, Andrew Judge¹, Khadija Ourradi¹, Dominique de Seny², Yunfei Li¹ and Mohammed Sharif¹, ¹University of Bristol, Bristol, United Kingdom, ²University of Liège, Liège, Belgium
Background/Purpose: C3 complement fragment (C3f) has been identified as a potential biomarker for evaluating osteoarthritis (OA). C3f is released during the catabolic degradation of C3b…
Abstract Number: 0304 • ACR Convergence 2022
Rheumatoid Arthritis Patients Who Switched Treatment from Adalimumab to Upadacitinib Demonstrate a Robust Reduction of Inflammation-related Biomarkers: Proteomics Analysis from the SELECT-COMPARE Phase 3 Study
Thierry Sornasse¹, Fang Cai², Heidi Camp³, In-Ho Song⁴ and Iain B McInnes⁵, ¹AbbVie, South San Francisco, CA, ²AbbVie, Redwood City, CA, ³Abbvie, Winnetka, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Upadacitinib 15 mg QD (UPA), an oral JAK inhibitor, showed greater efficacy compared to adalimumab (ADA) in patients (pts) with active rheumatoid arthritis (RA)…
Abstract Number: 0540 • ACR Convergence 2022
Evaluation of Traditional Laboratory Markers as Predictors of Renal Flares: A Post-hoc Analysis of Four Phase III Clinical Trials of SLE
Sandra Jägerback¹, Alvaro Gomez¹ and Ioannis Parodis², ¹Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In patients with systemic lupus erythematosus (SLE), renal involvement is associated with high morbidity, and renal flare is a major contributing factor to poor…
Abstract Number: 0659 • ACR Convergence 2022
Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets
Joshua Reynolds¹, Chandra Mohan², Yaxi Li² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Houston, Houston, TX
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) through an unknown mechanism. Diagnosis currently relies on clinical criteria and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].